References
1. Mirizzi PL. Sindrome del conducto hepatico. J Int Chir 1948;8:731–737.
2. Csendes A, Diaz JC, Burdiles P, et al. Mirrizzi Syndrome and cholcystobiliary fistula: a unifying classification. Br J Surg 1989;76:1139–1143.
3. Pemberton M, Wells AD. The Mirizzi syndrome. Postgrad Med J 1997;73:487–490.
4. McSherry CK, Ferstenberg H, Virshup M. The Mirizzi syndrome: Suggested classification and surgical therapy. Surg. Gastroenterol 1982;1:219–225.
5. Nagakawa T, Ohta T, Kayahara M, et al. A new classification of Mirizzi syndrome from diagnostic and therapeutic viewpoints. Hepatogastroenterology 1997;44:63–7.
6. Chan CY, Liau KH, Ho CK, et al. Mirizzi Syndrome: a diagnostic and operative challenge. Surg Journal of the Royal Colleges of Surgeons of Edinburgh and Ireland 2003;1:273–278.
7. Tan KY, Chng HC, Chen CY, et al. Mirizzi syndrome: noteworthy aspects of a retrospective study in one center. ANZ J Surg 2004;74:833–837.
8. Abou-Saif A, Al-Kawas FH. Complications of gallstone disease: Mirizzi syndrome, cholecystocholedochal fistula, and gallstone ileus. Am J Gastroenterology 2002;97:149–254.
9. Curet MN, Rosendale DE, Congilosi S. Mirizzi syndrome in a Native American Population. Am J Surg1994;168:616–621.
10. Atkinson BF, Ernst C, Herlyn M, et al. Gastrointestinal cancer associated antigen in immunoperoxidase assay. Cancer Res 1982;42:4820–4823.
11. Arends JW, Verstynen C, Bosman FT, et al. Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study. Hybridoma1983;2:219–229.
12. Perkins GL, Slater ED, Sanders GK, et al. Serum tumor markers. Am Fam Physician2003;68:1075–1088.
13. Mann DV, Edwards R, Ho S, et al. Elevated tumour marker CA 19-9: clinical interpretation and influence of obstructive jaundice. Eur Jour of Sur Onc 2000;26:474–479.
14. Pavai S, Yap SF. The clinical significance of elevated levels of serum CA 19-9. Med J Malaysia.2003;58:667–72.
15. Fan ST, Lan WY, Lee MJR, et al. Cholecysto-hepaticodochal fistula, the value of pre-operative recognition. Br J Surg 1985;72:743–744.
16. Ng WW, Tong KJ, Tam TN, et al. Clinical values of CA 19-9, CA 125 and CEA in malignant obstructive jaundice. Zhonghua Yi Xue Za Zhi 1995;55:438–446.
17. Peterli R, Meyer-Wyss B, Herzog U, et al. CA 19-9 has no value as a tumor marker in obstructive jaundice. Schweiz Med Wochenschr 199;129:77–79.
18. Magnani J, Steplewski Z, Koprowski H, et al. Identification of the gastrointestinal and pancreatic cancer associated antigen detected by monoclonal antibody 19-9 in the sera of patients as a mucin.Cancer Res 1983;43:5489–5492.
19. McFarlane IG. Hepatic clearance of serum glycoproteins. Clin Sci 1983;64:127–135.
20. Kim PN, Outwater EK, Mitchell DG. Mirizzi syndrome: evaluation by MR imaging. Am J Gastroenterol 1999;94:2546–2550.
21. Becker CD, Hassler H, Terrier F. Preoperative diagnosis of the Mirizzi syndrome: limitations of sonography and computed tomography.
American Journal of Roentgen 1984;143:591–596.
22. Dewar G, Chung SC, Li AK. Operative strategy in the Mirizzi syndrome. Surg Gynecol Obstet1990;171:157–159.
23. Berland LL, Lawson TL, Stanley RJ. CT appearance of Mirizzi syndrome. J Comput Assist Tomogr1984;8:165–166.
24. Choi BW, Kim MJ, Chung JJ, et al. Radiologic findings of Mirizzi syndrome with emphasis on MRI.Yonsei Medical Journal 2000;41:144–146.
25. Yip AWC, NG WS, Suen WS, et al. Type II Mirizzi syndrome: diagnosis by endoscopic retrograde cholangiopancreatography. J R Coll Surg Edin 1992;37:49–55.